• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Vi­a­tris weighs sale of Eu­ro­pean con­sumer health busi­ness — re­port

3 years ago
Deals
Pharma

Ad­di­tion­al man­u­fac­tur­ers in short sup­ply of gener­ic Adder­all

3 years ago
Pharma
Manufacturing

Mod­er­na gets Au­to­lus tar­get­ing tech via li­cens­ing deal; Atai re­ports PhI da­ta for kratom-based ther­a­py

3 years ago
News Briefing

Mer­ck pays Mod­er­na $250M to con­tin­ue Keytru­da, can­cer vac­cine com­bo stud­ies

3 years ago
Deals
R&D

Now with pos­i­tive PhI da­ta, DICE goes af­ter pub­lic of­fer­ing in search of $250M

3 years ago
Financing

De­spite $109M in­flux in Au­gust, Green­Light Bio­sciences brings out the axe to chop a quar­ter of its staff

3 years ago
People
R&D

With help from Lu­l­ule­mon founder’s ven­ture phil­an­thropy, Vi­ta adds sec­ond mus­cu­lar dy­s­tro­phy in­di­ca­tion to line­up

3 years ago
Financing
R&D

Evofem's ap­proved birth con­trol gel flops PhI­II for STI pre­ven­tion, ear­ly 2023 fil­ing plans ditched

3 years ago
R&D

At­las-backed biotech fo­cused on Hunt­ing­ton's dis­ease shuts down less than three years af­ter launch

3 years ago
R&D

Roy­al­ty Phar­ma bets Mer­ck­'s schiz­o­phre­nia drug can go where Pfiz­er, Take­da and Lund­beck­'s couldn’t

3 years ago
Financing
Deals

Months af­ter adding $60M to cof­fers, AI start­up Ter­ray nabs dis­cov­ery pact with Google's Cal­i­co

3 years ago
Deals
AI

‘Pluck those di­a­monds’: Bay­er’s Vi­vid­ion eyes up to nine on­col­o­gy tar­gets from Duke spin­out

3 years ago
Startups
Deals

Michael Ehlers and Ro­mesh Sub­ra­man­ian launch biotech with $50M, sea squirt-in­spired RNA-edit­ing tech

3 years ago
Financing
Startups

Now bank­rupt, Zosano sells off its drug de­liv­ery tech that once en­ticed No­vo Nordisk, Eli Lil­ly

3 years ago
Deals

Sang­amo gives an­oth­er up­date on ear­ly-stage Fab­ry pro­gram, en­ters tri­al ex­pan­sion phase

3 years ago
R&D
Cell/Gene Tx

FDA set­tles drug com­pound­ing suit, agrees to speed its re­view of bulk in­gre­di­ents

3 years ago
FDA+
Manufacturing

Wal­mart buys in­to phar­ma re­search, fol­low­ing in foot­steps of CVS and Wal­greens

3 years ago
Pharma

Am­neal lays off more than a dozen em­ploy­ees at Long Is­land fa­cil­i­ty as op­er­a­tions wind down

3 years ago
Manufacturing

FDA signs off on GSK la­bel ex­pan­sion for Tdap vac­cine

3 years ago
FDA+

More ear­ly da­ta ma­nip­u­la­tion is­sues tied to No­var­tis block­buster as Na­ture re­tracts pa­per

3 years ago
R&D
Cell/Gene Tx

As­traZeneca and GSK set­tle tal­ent feud in court — again

3 years ago
People
Pharma

Mar­ket­ingRx roundup: Phar­ma, agen­cies turn up for World Men­tal Health Day; Hori­zon, Ver­tex make best work­place list

3 years ago
Pharma
Marketing

#Phar­ma­Tok: Am­gen, AZ join grow­ing num­ber of phar­ma mar­keters on the so­cial video chan­nel

3 years ago
Pharma
Marketing

Pfiz­er ex­ec de­nies vac­cine ne­go­ti­a­tions via text mes­sage in grilling be­fore Eu­ro­pean Par­lia­ment

3 years ago
Deals
Pharma
First page Previous page 446447448449450451452 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times